Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:57 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
NCT03926143 · Bayer · PHASE2 · terminated · last registry update 2023-08-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to strategic company decisions, the development of anetumab ravtansine was stopped.” | – | Registry record, Bayer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MSLN within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-04-16Also stopped (terminated): National Cancer Institute (NCI), LMB-100 + pembrolizumab (NCT04027946)
- 2024-02-02Results posted on the registry: National Cancer Institute (NCI), LMB-100 + ipilimumab (NCT04840615)
- 2024-02-02Also stopped (terminated): National Cancer Institute (NCI), LMB-100 + ipilimumab (NCT04840615)
- 2024-02-02Also stopped (withdrawn): National Cancer Institute (NCI), LMB-100 (NCT05375825)
- 2023-07-18Results posted on the registry: National Cancer Institute (NCI), LMB-100 + pembrolizumab (NCT04027946)
- 2023-01-06Also stopped (terminated): Mayo Clinic, Anetumab Ravtansine + Atezolizumab (NCT03455556)
- 2022-09-22Results posted on the registry: Morphotek, MORAb-009 (Amatuximab) + Pemetrexed (NCT00738582)
- 2022-08-23Results posted on the registry: National Cancer Institute (NCI), LMB-100 + nab-paclitaxel (NCT02798536)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision